How to profit from uranium shortages

While gold has been struggling of late, the other yellow metal, uranium, continues to glow. Spot prices have risen eightfold over the past few years to more than $60 a pound. As nuclear power experiences a renaissance, how can investors best play uranium shortages?

While gold has been struggling of late, the other yellow metal, uranium, continues to glow. Spot prices have risen eightfold over the past few years to more than $60 a pound. The latest uptick, a 7% jump from last week's level, was spurred by the news that Cameco, the world's biggest uranium producer, had suffered a flood at its Cigar Lake mine and that it may now never produce.

According to one analyst, the flood is the equivalent of the oil market losing Saudi Arabia; the 18 million pounds it was supposed to produce from 2008 amount to more than 10% of last year's global demand. A tight market is tightening further: demand was already set to exceed supply by 25 million pounds in 2008, notes Sean Brodrick on TheStreet.com. Now the gap will be 32 million pounds.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Andrew Van Sickle
Editor, MoneyWeek

Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.

After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.

His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.

Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.